|Day Low/High||331.24 / 334.03|
|52 Wk Low/High||223.02 / 337.73|
Medtronic, Abbott Labs and Becton Dickinson appear to be offering buying opportunities.
Let's play out what's allowing our markets to fly: Earnings.
A bullish market and another quant upgrade could push BSX past our $31 target.
TheStreet's Jim Cramer weighs in on Becton Dickinson's BDX purchase of Bard BCR for $24 billion.
Bard was shopped to BD as an acquisition target about 15 years ago
Here are five things you must know for Monday, April 24.
We ought to open our eyes to what we don't care about, to what's still made here.
Their overseas business has been carrying them.
We know that we are in the era when index managers are ascendant.
There are nearly too many surging sectors to count.
There is so much buying power in so many new areas.
Traders should look to go long BCR near $210 if it pulls back.
Buyers should stay on the sidelines of Bard until a base is formed, potentially at a lower level.
Two significant, but subtle forces may threaten the group in the next 12 months.
We would begin trimming our position with a stop-loss just below $180.
With no top in sight, we remain bulls on this name.
Jim Cramer answered viewers' Twitter from the floor of the New York Stock Exchange, commenting on Qorvo (QRVO), Celgene (CELG), and Boston Scientific (BSX).
There are some good buying ideas among these stocks.